Back to Search
Start Over
Arginase as a target for treatment of myocardial ischemia-reperfusion injury
- Source :
- European journal of pharmacology. 720(1-3)
- Publication Year :
- 2013
-
Abstract
- Two distinct enzymes of arginase (1 and 2) are critically regulating nitric oxide (NO) bioavailability by competing with NO synthase for their common substrate l-arginine. Increased expression and activity of arginase is observed in atherosclerosis and myocardial ischemia-reperfusion (I/R). Several studies have demonstrated a key pathophysiological role of increased activity of arginase during I/R. Pharmacological inhibition of arginase results in restoration of NO availability and salvage of myocardium during I/R. Arginase inhibition might be a promising therapeutic strategy for the limitation of myocardial injury in acute myocardial infarction. Current understanding of the role of arginase and efficacy of arginase inhibition during myocardial I/R is reviewed in the present article.
- Subjects :
- Pharmacology
chemistry.chemical_classification
Myocardial ischemia
Arginase
business.industry
Myocardial Reperfusion Injury
medicine.disease
Nitric Oxide
Pathophysiology
Nitric oxide
chemistry.chemical_compound
Enzyme
Biochemistry
chemistry
medicine
Animals
Humans
Myocardial infarction
business
Reperfusion injury
Therapeutic strategy
Subjects
Details
- ISSN :
- 18790712
- Volume :
- 720
- Issue :
- 1-3
- Database :
- OpenAIRE
- Journal :
- European journal of pharmacology
- Accession number :
- edsair.doi.dedup.....7058b05f9899482f01b90abe3e06cf86